Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches, says GlobalData

Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches, says GlobalData

LONDON, UK (GlobalData), 11 February 2014 - The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%, according to a new report from research and consulting firm GlobalData.

The company's latest report* states that out of the eight major markets — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively.

According to GlobalData, the growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively.

Christopher Pace, Ph.D., GlobalData's Analyst covering Infectious Diseases, says: "Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine."

However, GlobalData believes that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace.

Pace says: "In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults.

"For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period."

*PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

-ENDS-

-NOTES TO EDITORS-

This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at [email protected]

Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Healthcare sector, or connect with us on:

Facebook | LinkedIn | Twitter 

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.